TMCI
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Trades at a low multiple of sales, but lacks the earnings to support a Graham Number valuation.
- Low P/S ratio of 0.60
- No P/E due to negative earnings
- Negative forward P/E
Revenue growth is trending downward, which is a critical failure for a medical device company.
- Recent EPS beats
- Negative YoY and Q/Q revenue growth
- Lack of clear path to profitability
Historical price action shows a consistent and severe downward trend.
- 5-year return of -92.3%
- 1-year return of -69.4%
Balance sheet liquidity is the company's strongest attribute, preventing immediate distress.
- Piotroski F-Score of 5/9
- High Current Ratio (4.31)
- Negative ROE and ROA
Non-dividend paying growth/speculative stock.
- No dividend payments
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for TMCI and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
TMCI
Treace Medical Concepts, Inc.
Primary
|
-92.3% | -92.6% | -69.4% | -71.0% | +58.9% | -2.0% |
|
JYNT
The Joint Corp.
Peer
|
-83.5% | -44.4% | -12.2% | +8.3% | +2.6% | +1.5% |
|
IPHA
Innate Pharma S.A.
Peer
|
-67.1% | -58.3% | -22.5% | -30.5% | -9.0% | +2.9% |
|
OPRX
OptimizeRx Corporation
Peer
|
-87.6% | -55.5% | -23.2% | -68.6% | -2.0% | -1.5% |
|
HYPR
Hyperfine, Inc.
Peer
|
-88.1% | -17.1% | +81.4% | -30.9% | +2.5% | +7.1% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
TMCI
Treace Medical Concepts, Inc.
|
BEARISH | $127.63M | - | -58.9% | -27.7% | $1.97 | |
|
JYNT
The Joint Corp.
|
BEARISH | $125.04M | - | -1.5% | 5.3% | $8.73 | Compare |
|
IPHA
Innate Pharma S.A.
|
BEARISH | $132.24M | - | -% | -% | $1.41 | Compare |
|
OPRX
OptimizeRx Corporation
|
NEUTRAL | $120.08M | 23.7 | 4.2% | 4.7% | $6.4 | Compare |
|
HYPR
Hyperfine, Inc.
|
NEUTRAL | $119.21M | - | -79.0% | -262.3% | $1.21 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-01 | HAIR MARK | Chief Financial Officer | Stock Award | 100,000 | - |
| 2026-02-10 | SCANLAN SEAN F | Officer | Option Exercise | 16,875 | $17,719 |
| 2026-01-22 | GUGLIELMINO GAETANO M | Officer | Stock Award | 150,000 | - |
| 2026-01-22 | HAIR MARK | Chief Financial Officer | Stock Award | 375,000 | - |
| 2026-01-22 | SCANLAN SEAN F | Chief Technology Officer | Stock Award | 262,500 | - |
| 2026-01-22 | TREACE JOHN T. | Chief Executive Officer | Stock Award | 250,000 | - |
| 2026-01-22 | ELDER SCOT MICHAEL | Officer | Stock Award | 262,500 | - |
| 2026-01-21 | SCANLAN SEAN F | Chief Technology Officer | Option Exercise | 53,500 | $38,520 |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning TMCI from our newsroom.